April 29, 2014 / 10:40 AM / 4 years ago

Amicus Therapeutics fat disorder drug effective in trial

April 29 (Reuters) - Amicus Therapeutics Inc said its lead drug to treat fat-storage disorder was found effective in patients after 12 months of treatment in a late-stage trial.

The company’s shares jumped about 33 percent in premarket trading. They closed at $1.84 on the Nasdaq on Monday.

The trial evaluated the drug, migalastat, as a form of monotherapy for Fabry disease patients. (Reporting by Natalie Grover in Bangalore; Editing by Don Sebastian)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below